research Nemolizumab Treatment for Severe Atopic Dermatitis Led to the Simultaneous Improvement of Coexisting Refractory Alopecia Areata: A Case Report
Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
Search
for
Sort by
Research
30-60 / 1000+ results
research Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report
Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
research Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
Belimumab reduces disease activity, steroid use, and flares in lupus patients.
research Dissecting cellulitis of the scalp successfully treated with infliximab
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Real-World Outcomes and Healthcare Utilization of Lanadelumab in Spain: Insights from First Cohort of Difficult-to-Treat Hereditary Angioedema Cases
Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
research SnapshotDx Quiz: September 2018
Tofacitinib may help regrow hair in alopecia areata patients.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research 24 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
research Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review
A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.
research Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa
Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
research AB0442 Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort
Belimumab effectively controls SLE disease activity and reduces steroid use.
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients
ACTH may be an effective first-line treatment for acute calcium pyrophosphate crystal arthritis.
research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
research Transplantation immunology: Solid organ and bone marrow
Transplant success has improved with better immunosuppressive drugs and donor matching.
research First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases
Thymus transplantation successfully restored immune function in infants with FOXN1 deficiency.
research Adverse effects of voriconazole: Over a decade of use
Voriconazole can cause serious side effects, especially in long-term use.
research Treatment strategies for alopecia
Some treatments work for common baldness, but there's less evidence for other hair loss types, and more research is needed.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
research Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer
A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
research Scarring Alopecia
Early and aggressive treatment of scarring alopecia is important to prevent further hair follicle damage.
research Regulatory T Cell Heterogeneity in the Steady State and Tumor
Regulatory T cells adapt to different environments to control inflammation and support tissue repair.
research Mendelian Randomization Identifies CD25+ CD4+ Tregs and Plasma Proteins in Androgenetic Alopecia Pathogenesis
Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.
research Alemtuzumab-Induced Secondary Autoimmune Skin Disorders as Side Effects of Multiple Sclerosis Therapy: Problem That Can Be Influenced or Fate? A Narrative Overview of The Literature A Neuroprotective Role of Vitamin D?
Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
research Calcineurin-based immunosuppression in renal transplantation : focus on efficacy, the role of steroids, and the cardiovascular risk
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.